Victory Square Technologies Inc. VSQTF
0.33 USD -0.01 (-2.34%)
At closeNov 2, 2026, 4:00 PM EST
0.3391 Day range 0.3391
0.2933 52-week range 0.665
- YTD
- -38.20%
- 1 year
- -44.79%
- Market cap
- 34.42M
- EPS (ttm)
- 0.04
- P/E ratio
- 8.25
- YTD return
- -38.20%
- 1-year return
- -44.79%
- Volume
- 2.50K
- Avg volume
- 35.87K
- Open
- 0.3391
- Previous close
- 0.3379
- Day's range
- 0.3391 – 0.3391
- 52-week range
- 0.2933 – 0.665
3M -0.1544 (-31.29%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 29, 2024 | Sep 1, 2024 | 0.00 | 0.08 | — | — |
| Aug 30, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| May 30, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Apr 30, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
| Nov 29, 2023 | Sep 1, 2023 | 0.00 | -0.02 | — | — |
| Aug 29, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
News
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology 
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform 
Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List 
Victory Square Technologies Reports First-Half 2026 Revenue of $53.0 Million and Net Income of $6.5 Million 
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million 
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million 
Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A 
Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston 
Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances 
Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations
Your note
Sign in to keep a note on VSQTF — it syncs with the Stock Master app.